Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Epidemiology and Risk Factors for Severe Delayed Drug Hypersensitivity Reactions

Author(s): Eva S.R. Gomes*, Maria L. Marques and Frederico S. Regateiro

Volume 25, Issue 36, 2019

Page: [3799 - 3812] Pages: 14

DOI: 10.2174/1381612825666191105115346

Price: $65

Abstract

Severe delayed drug hypersensitivity reactions comprise different clinical entities and can involve different immune-mediated mechanisms. Common examples are severe cutaneous adverse reactions and druginduced internal organ injuries.

The incidence of such reactions is overall low but seems to be on the rise reaching numbers as high as 9 per million individuals-years in the case of SJS/TEN and DRESS. Such conditions carry an important associated morbidity, and mortality can attain 40% in SJS/TEN patients, making these hypersensitivity reactions important targets when implementing preventive measures.

Several risk factors have been identified for reaction severity; some are transverse, such as older age and underlying chronic diseases. The recent advances in pharmacogenetics allowed the identification of specific populations with higher risk and permitted strategic avoidance of certain drugs being HLA-B*57:01 screening in patients initiating abacavir the best successful example. In this work, we reviewed the epidemiology of SCARs and liver/kidney/lung drug-induced immune-mediated reactions. We focus on particular aspects such as prevalence and incidence, drugs involved, mortality and risk factors.

Keywords: Drug hypersensitivity, severe delayed adverse drug reactions, epidemiology, risk factors, SCARs, immune-mediated.

[1]
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200-5.
[http://dx.doi.org/10.1001/jama.279.15.1200] [PMID: 9555760]
[2]
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329(7456): 15-9.
[http://dx.doi.org/10.1136/bmj.329.7456.15] [PMID: 15231615]
[3]
Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5(4): 309-16.
[http://dx.doi.org/10.1097/01.all.0000173785.81024.33] [PMID: 15985812]
[4]
Johansson SGO, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy organization, october 2003. J Allergy Clin Immunol 2004; 113(5): 832-6.
[http://dx.doi.org/10.1016/j.jaci.2003.12.591] [PMID: 15131563]
[5]
Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the boston collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256(24): 3358-63.
[http://dx.doi.org/10.1001/jama.1986.03380240052027] [PMID: 2946876]
[6]
Noguera-Morel L, Hernández-Martín Á, Torrelo A. Cutaneous drug reactions in the pediatric population. Pediatr Clin North Am 2014; 61(2): 403-26.
[http://dx.doi.org/10.1016/j.pcl.2013.12.001] [PMID: 24636653]
[7]
Hunziker T, Künzi U-P, Braunschweig S, Zehnder D, Hoigné R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52(4): 388-93.
[http://dx.doi.org/10.1111/j.1398-9995.1997.tb01017.x] [PMID: 9188919]
[8]
Mockenhaupt M. Severe cutaneous adverse reactions Braun-falco’s dermatology. 3rd ed. Heidelberg: Springer 2009; pp. 473-84.
[http://dx.doi.org/10.1007/978-3-540-29316-3_34]
[9]
Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy 2019; 74(1): 14-27.
[http://dx.doi.org/10.1111/all.13562] [PMID: 30028512]
[10]
Casagranda A, Suppa M, Dehavay F, Del Marmol V. Overlapping DRESS and stevens-johnson syndrome: case report and review of the literature. Case Rep Dermatol 2017; 9(2): 1-7.
[http://dx.doi.org/10.1159/000475802] [PMID: 28611628]
[11]
Bouvresse S, Valeyrie-Allanore L, Ortonne N, et al. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis 2012; 7: 72.
[http://dx.doi.org/10.1186/1750-1172-7-72] [PMID: 23009177]
[12]
Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149(5): 1018-22.
[http://dx.doi.org/10.1111/j.1365-2133.2003.05584.x] [PMID: 14632808]
[13]
Hernández-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006; 37(7): 899-902.
[http://dx.doi.org/10.1016/j.arcmed.2006.03.010] [PMID: 16971233]
[14]
Danza A, López M, Vola M, Álvarez-Rocha A. Reacciones adversas cutáneas a medicamentos: vigilancia durante un año en un hospital universitario. Uruguay 2008-2009. Rev Med Chil 2010; 138(11): 1403-9.
[http://dx.doi.org/10.4067/S0034-98872010001200009] [PMID: 21279253]
[15]
Kim HS, Tang MM. Cutaneous adverse drug reactions: a four-year audit from a district hospital in johor, malaysia. Med J Malaysia 2018; 73(6): 397-9.
[PMID: 30647211]
[16]
Kelly JP, Auquier A, Rzany B, et al. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 1995; 48(9): 1099-108.
[http://dx.doi.org/10.1016/0895-4356(95)00004-N] [PMID: 7636511]
[17]
Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of stevens-johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333(24): 1600-7.
[http://dx.doi.org/10.1056/NEJM199512143332404] [PMID: 7477195]
[18]
Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128(1): 35-44.
[http://dx.doi.org/10.1038/sj.jid.5701033] [PMID: 17805350]
[19]
Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157(5): 989-96.
[http://dx.doi.org/10.1111/j.1365-2133.2007.08156.x] [PMID: 17854366]
[20]
Roujeau J-C, Guillaume J-C, Fabre J-P, Penso D, Fléchet M-L, Girre J-P. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126(1): 37-42.
[http://dx.doi.org/10.1001/archderm.1990.01670250043005] [PMID: 2134982]
[21]
Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and stevens-johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991; 127(6): 839-42.
[http://dx.doi.org/10.1001/archderm.1991.01680050083008] [PMID: 2036029]
[22]
Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, stevens-johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49(7): 769-73.
[http://dx.doi.org/10.1016/0895-4356(96)00035-2] [PMID: 8691227]
[23]
Diphoorn J, Cazzaniga S, Gamba C, et al. REACT-Lombardia study group. Incidence, causative factors and mortality rates of stevens-johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern italy: data from the REACT registry. Pharmacoepidemiol Drug Saf 2016; 25(2): 196-203.
[http://dx.doi.org/10.1002/pds.3937] [PMID: 26687641]
[24]
Frey N, Jossi J, Bodmer M, et al. The Epidemiology of stevens-johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol 2017; 137(6): 1240-7.
[http://dx.doi.org/10.1016/j.jid.2017.01.031] [PMID: 28202399]
[25]
Velasco-Tirado V, Alonso-Sardón M, Cosano-Quero A, et al. Life-threatening dermatoses: stevens-johnson syndrome and toxic epidermal necrolysis. impact on the spanish public health system (2010-2015). PLoS One 2018; 13(6)e0198582
[http://dx.doi.org/10.1371/journal.pone.0198582] [PMID: 29912947]
[26]
Yang M-S, Lee JY, Kim J, et al. Incidence of stevens-johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in korea. PLoS One 2016; 11(11)e0165933
[http://dx.doi.org/10.1371/journal.pone.0165933] [PMID: 27835661]
[27]
White ML, Chodosh J, Jang J, Dohlman C. Incidence of stevens-johnson syndrome and chemical burns to the eye. Cornea 2015; 34(12): 1527-33.
[http://dx.doi.org/10.1097/ICO.0000000000000646] [PMID: 26488629]
[28]
Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of stevens-johnson syndrome and toxic epidermal necrolysis in united states adults. J Invest Dermatol 2016; 136(7): 1387-97.
[http://dx.doi.org/10.1016/j.jid.2016.03.023] [PMID: 27039263]
[29]
Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric stevens-johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 2017; 76(5): 811-817: e4.
[http://dx.doi.org/10.1016/j.jaad.2016.12.024] [PMID: 28285784]
[30]
Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol 2018; 35(2): 182-7.
[http://dx.doi.org/10.1111/pde.13383] [PMID: 29315761]
[31]
Hiransuthikul A, Rattananupong T, Klaewsongkram J, Rerknimitr P, Pongprutthipan M, Ruxrungtham K. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in thailand. Allergol Int 2016; 65(4): 432-8.
[http://dx.doi.org/10.1016/j.alit.2016.04.001] [PMID: 27134114]
[32]
Muller P, Dubreil P, Mahé A, et al. Drug hypersensitivity syndrome in a west-indian population. Eur J Dermatol 2003; 13(5): 478-81.
[PMID: 14693494]
[33]
Wolfson AR, Zhou L, Li Y, Phadke NA, Chow OA, Blumenthal KG. Drug reaction with eosinophilia and systemic symptoms (dress) syndrome identified in the electronic health record allergy module. J Allergy Clin Immunol Pract 2019; 7(2): 633-40.
[http://dx.doi.org/10.1016/j.jaip.2018.08.013] [PMID: 30176295]
[34]
Sidoroff A, Halevy S, Bavinck JNB, Vaillant L, Roujeau J-C. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol 2001; 28(3): 113-9.
[http://dx.doi.org/10.1034/j.1600-0560.2001.028003113.x] [PMID: 11168761]
[35]
Sidoroff A. Acute generalized exanthematous pustulosis. Chem Immunol Allergy 2012; 97: 139-48.
[http://dx.doi.org/10.1159/000335625] [PMID: 22613859]
[36]
Dodiuk-GAD RP, Laws PM, Shear NH. Epidemiology of severe cutaneous drug hypersensitivity. Semin Cutan Med Surg 2014; 33(1): 2-9.
[37]
Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169(5): 1071-80.
[http://dx.doi.org/10.1111/bjd.12501] [PMID: 23855313]
[38]
Botelho LFF, Porro AM, Enokihara MMSS, Tomimori J. Adverse cutaneous drug reactions in a single quaternary referral hospital. Int J Dermatol 2016; 55(4): e198-203.
[http://dx.doi.org/10.1111/ijd.13126] [PMID: 26710962]
[39]
Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol 2013; 32(1): 41-5.
[http://dx.doi.org/10.3109/15569527.2012.702837] [PMID: 22812902]
[40]
Su P, Aw CWD. Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study. Int J Dermatol 2014; 53(11): 1339-45.
[http://dx.doi.org/10.1111/ijd.12118] [PMID: 25070588]
[41]
Roujeau J-C. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209(2): 123-9.
[http://dx.doi.org/10.1016/j.tox.2004.12.022] [PMID: 15767024]
[42]
Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169(5): 1071-80.
[http://dx.doi.org/10.1111/bjd.12501] [PMID: 23855313] [http://dx.doi.org/10.1038/jid.2012.510] [PMID: 23389396]
[43]
Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115(2): 149-53.
[http://dx.doi.org/10.1046/j.1523-1747.2000.00061.x] [PMID: 10951229]
[44]
Namdar T, von Wild T, Siemers F, et al. Does hypernatremia impact mortality in toxic epidermal necrolysis? Ger Med Sci 2010; 8: Doc30.
[PMID: 21063469]
[45]
Yun SJ, Choi M-S, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology (Basel) 2008; 217(3): 254-9.
[http://dx.doi.org/10.1159/000148255] [PMID: 18667824]
[46]
Yeong E-K, Lee C-H, Hu F-C. M Z W. Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis. J Intensive Care Med 2011; 26(4): 250-4.
[http://dx.doi.org/10.1177/0885066610390466] [PMID: 21887862]
[47]
Yang M-S, Kang M-G, Jung J-W, et al. Clinical features and prognostic factors in severe cutaneous drug reactions. Int Arch Allergy Immunol 2013; 162(4): 346-54.
[http://dx.doi.org/10.1159/000354918] [PMID: 24193402]
[48]
Noe MH, Rosenbach M, Hubbard RA, et al. Development and validation of a risk prediction model for in-hospital mortality among patients with stevens-johnson syndrome/toxic epidermal necrolysis-ABCD-10. JAMA Dermatol 2019; 155(4): 448-54.
[http://dx.doi.org/10.1001/jamadermatol.2018.5605] [PMID: 30840032]
[49]
Monteiro D, Egipto P, Barbosa J, et al. Nine years of a single referral center management of stevens-johnson syndrome and toxic epidermal necrolysis (Lyell’s syndrome). Cutan Ocul Toxicol 2017; 36(2): 163-8.
[http://dx.doi.org/10.1080/15569527.2016.1218501] [PMID: 27487073]
[50]
Lalosevic J, Nikolic M, Gajic-Veljic M, Skiljevic D, Medenica L. Stevens-johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. Int J Dermatol 2015; 54(8): 978-84.
[http://dx.doi.org/10.1111/ijd.12702] [PMID: 25385069]
[51]
Tran AK, Sidhu S. Stevens-johnson syndrome and toxic epidermal necrolysis - an australian analysis of treatment outcomes and mortality. J Dermatolog Treat 2019; 30(7): 718-23.
[http://dx.doi.org/10.1080/09546634.2019.1568380] [PMID: 30632424]
[52]
Weinand C, Xu W, Perbix W, et al. 27 years of a single burn centre experience with Stevens-johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. Burns 2013; 39(7): 1449-55.
[http://dx.doi.org/10.1016/j.burns.2013.03.011] [PMID: 23702222]
[53]
Oen IMMH, van der Vlies CH, Roeleveld YWF, Dokter J, Hop MJ, van Baar ME. Epidemiology and costs of patients with toxic epidermal necrolysis: a 27-year retrospective study. J Eur Acad Dermatol Venereol 2015; 29(12): 2444-50.
[http://dx.doi.org/10.1111/jdv.13352] [PMID: 26416341]
[54]
Nizamoglu M, Ward JA, Frew Q, et al. Improving mortality outcomes of Stevens-johnson syndrome/toxic epidermal necrolysis: a regional burns centre experience. Burns 2018; 44(3): 603-11.
[http://dx.doi.org/10.1016/j.burns.2017.09.015] [PMID: 29029855]
[55]
Dilokthornsakul P, Sawangjit R, Inprasong C, et al. Healthcare utilization and cost of stevens-johnson syndrome and toxic epidermal necrolysis management in thailand. J Postgrad Med 2016; 62(2): 109-14.
[http://dx.doi.org/10.4103/0022-3859.180571] [PMID: 27089110]
[56]
Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced stevens-johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med 2011; 57(2): 115-9.
[http://dx.doi.org/10.4103/0022-3859.81865] [PMID: 21654132]
[57]
Yamane Y, Aihara M, Ikezawa Z. Analysis of stevens-johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007; 56(4): 419-25.
[http://dx.doi.org/10.2332/allergolint.O-07-483] [PMID: 17713361]
[58]
Chen Y-C, Chiu H-C, Chu C-Y. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010; 146(12): 1373-9.
[http://dx.doi.org/10.1001/archdermatol.2010.198] [PMID: 20713773]
[59]
Wei C-H, Chung-Yee Hui R, Chang C-J, et al. Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol 2011; 21(6): 930-7.
[http://dx.doi.org/10.1684/ejd.2011.1550] [PMID: 21951554]
[60]
Nam YH, Park MR, Nam HJ, et al. Drug reaction with eosinophilia and systemic symptoms syndrome is not uncommon and shows better clinical outcome than generally recognised. Allergol Immunopathol (Madr) 2015; 43(1): 19-24.
[http://dx.doi.org/10.1016/j.aller.2013.08.003] [PMID: 24388810]
[61]
Walsh S, Diaz-Cano S, Higgins E, et al. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol 2013; 168(2): 391-401.
[http://dx.doi.org/10.1111/bjd.12081] [PMID: 23034060]
[62]
Loo CH, Tan WC, Khor YH, Chan LC. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in penang, malaysia. Med J Malaysia 2018; 73(2): 73-7.
[PMID: 29703869]
[63]
Teo YX, Walsh SA. Severe adverse drug reactions. Clin Med (Lond) 2016; 16(1): 79-83.
[http://dx.doi.org/10.7861/clinmedicine.16-1-79] [PMID: 26833523]
[64]
Halevy S, Ghislain P-D, Mockenhaupt M, et al. EuroSCAR study group. allopurinol is the most common cause of stevens-johnson syndrome and toxic epidermal necrolysis in europe and israel. J Am Acad Dermatol 2008; 58(1): 25-32.
[http://dx.doi.org/10.1016/j.jaad.2007.08.036] [PMID: 17919772]
[65]
Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 2014; 25(2): 225-34.
[http://dx.doi.org/10.1097/CAD.0000000000000032] [PMID: 24108082]
[66]
Saissi E-H, Beau-Salinas F, Jonville-Béra A-P, Lorette G, Autret-Leca E. Centres régionaux de pharmacovigilance. Médicaments associés à la survenue d’une pustulose exanthématique aiguë généralisée. Ann Dermatol Venereol 2003; 130(6-7): 612-8.
[PMID: 13679697]
[67]
Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124(7): 588-97.
[http://dx.doi.org/10.1016/j.amjmed.2011.01.017] [PMID: 21592453]
[68]
Klaewsongkram J, Sukasem C, Thantiworasit P, et al. ThaiSCAR study group. Analysis of HLA-B allelic variation and IFN-γ ELISpot responses in patients with severe cutaneous adverse reactions associated with drugs. J Allergy Clin Immunol Pract 2019; 7(1): 219-227: e4.
[http://dx.doi.org/10.1016/j.jaip.2018.05.004] [PMID: 29800753]
[69]
Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens-johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case-control study. Drug Saf 2019; 42(1): 55-66.
[http://dx.doi.org/10.1007/s40264-018-0711-x] [PMID: 30112729]
[70]
Chen C-B, Wu M-Y, Ng CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res 2018; 10: 1259-73.
[http://dx.doi.org/10.2147/CMAR.S163391] [PMID: 29844705]
[71]
Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of stevens-johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009; 123(2): e297-304.
[http://dx.doi.org/10.1542/peds.2008-1923] [PMID: 19153164]
[72]
Dibek Misirlioglu E, Guvenir H, Bahceci S, et al. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract 2017; 5(3): 757-63.
[http://dx.doi.org/10.1016/j.jaip.2017.02.013] [PMID: 28351788]
[73]
Oh HL, Kang DY, Kang H-R, et al. Korean severe cutaneous adverse reactions consortium. severe cutaneous adverse reactions in korean pediatric patients: a study from the korea scar registry. Allergy Asthma Immunol Res 2019; 11(2): 241-53.
[http://dx.doi.org/10.4168/aair.2019.11.2.241] [PMID: 30661316]
[74]
Lin Y-F, Yang C-H, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis 2014; 58(10): 1377-85.
[http://dx.doi.org/10.1093/cid/ciu126] [PMID: 24599767]
[75]
Lebrun-Vignes B, Guy C, Jean-Pastor M-J, Gras-Champel V, Zenut M. Is acetaminophen associated with a risk of stevens-johnson syndrome and toxic epidermal necrolysis? Analysis of the french pharmacovigilance database. Br J Clin Pharmacol 2018; 84(2): 331-8.
[http://dx.doi.org/10.1111/bcp.13445] [PMID: 28963996]
[76]
Lee S-Y, Nam YH, Koh Y-I, et al. Phenotypes of severe cutaneous adverse reactions caused by nonsteroidal anti-inflammatory drugs. Allergy Asthma Immunol Res 2019; 11(2): 212-21.
[http://dx.doi.org/10.4168/aair.2019.11.2.212] [PMID: 30661313]
[77]
White KD, Abe R, Ardern-Jones M, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract 2018; 6(1): 38-69.
[http://dx.doi.org/10.1016/j.jaip.2017.11.023] [PMID: 29310768]
[78]
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 2018; 54(1): 147-76.
[http://dx.doi.org/10.1007/s12016-017-8654-z] [PMID: 29188475]
[79]
Mullan KA, Anderson A, Illing PT, Kwan P, Purcell AW, Mifsud NA. HLA-associated antiepileptic drug-induced cutaneous adverse reactions. HLA 2019; 93(6): 417-35.
[http://dx.doi.org/10.1111/tan.13530] [PMID: 30895730]
[80]
Chen C-B, Abe R, Pan R-Y, et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res 2018; 20186431694
[http://dx.doi.org/10.1155/2018/6431694] [PMID: 29651444]
[81]
Pan R-Y, Dao R-L, Hung S-I, Chung W-H. Pharmacogenomic advances in the prediction and prevention of cutaneous idiosyncratic drug reactions. Clin Pharmacol Ther 2017; 102(1): 86-97.
[http://dx.doi.org/10.1002/cpt.683] [PMID: 28295240]
[82]
Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328(23): 1670-4.
[http://dx.doi.org/10.1056/NEJM199306103282304] [PMID: 8487826]
[83]
Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64(8): 2529-36.
[http://dx.doi.org/10.1002/art.34488] [PMID: 22488501]
[84]
Chan H-L, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, stevens-johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126(1): 43-7.
[http://dx.doi.org/10.1001/archderm.1990.01670250049006] [PMID: 2404462]
[85]
Park H-W, Kim S-H, Chang Y-S, et al. The fas signaling pathway is a common genetic risk factor for severe cutaneous drug adverse reactions across diverse drugs. Allergy Asthma Immunol Res 2018; 10(5): 555-61.
[http://dx.doi.org/10.4168/aair.2018.10.5.555] [PMID: 30088374]
[86]
Schutte RJ, Sun Y, Li D, Zhang F, Ostrov DA. Human leukocyte antigen associations in drug hypersensitivity reactions. Clin Lab Med 2018; 38(4): 669-77.
[http://dx.doi.org/10.1016/j.cll.2018.08.002] [PMID: 30420060]
[87]
Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359(9312): 1121-2.
[http://dx.doi.org/10.1016/S0140-6736(02)08158-8] [PMID: 11943262]
[88]
Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359(9308): 727-32.
[http://dx.doi.org/10.1016/S0140-6736(02)07873-X] [PMID: 11888582]
[89]
Simon M, Elizabeth P, Giampiero C, et al. HLA-B*5701 Screening for Hypersensitivity to Abacavir. N Engl J Med 2008; 12.
[90]
Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46(7): 1111-8.
[http://dx.doi.org/10.1086/529382] [PMID: 18444831]
[91]
White KD, Chung W-H, Hung S-I, Mallal S, Phillips EJ. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J Allergy Clin Immunol 2015; 136(2): 219-34.
[http://dx.doi.org/10.1016/j.jaci.2015.05.050] [PMID: 26254049]
[92]
Mounzer K, Hsu R, Fusco JS, et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study. AIDS Res Ther 2019; 16(1): 1.
[http://dx.doi.org/10.1186/s12981-019-0217-3] [PMID: 30651100]
[93]
Chung W-H, Hung S-I, Hong H-S, et al. Medical genetics: a marker for stevens-johnson syndrome. Nature 2004; 428(6982): 486-6.
[http://dx.doi.org/10.1038/428486a] [PMID: 15057820]
[94]
Man CBL, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48(5): 1015-8.
[http://dx.doi.org/10.1111/j.1528-1167.2007.01022.x] [PMID: 17509004]
[95]
Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of stevens-johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9(10): 1543-6.
[http://dx.doi.org/10.2217/14622416.9.10.1543] [PMID: 18855540]
[96]
Amstutz U, Shear NH, Rieder MJ, et al. CPNDS clinical recommendation group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; 55(4): 496-506.
[http://dx.doi.org/10.1111/epi.12564] [PMID: 24597466]
[97]
Genin E, Chen D-P, Hung S-I, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014; 14(3): 281-8.
[http://dx.doi.org/10.1038/tpj.2013.40] [PMID: 24322785]
[98]
Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20(5): 1034-41.
[http://dx.doi.org/10.1093/hmg/ddq537] [PMID: 21149285]
[99]
McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364(12): 1134-43.
[http://dx.doi.org/10.1056/NEJMoa1013297] [PMID: 21428769]
[100]
Hung S-I, Chung W-H, Liou L-B, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102(11): 4134-9.
[http://dx.doi.org/10.1073/pnas.0409500102] [PMID: 15743917]
[101]
Cheng L, Xiong Y, Qin CZ, et al. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in han chinese patients: a multicentre retrospective case-control clinical study. Br J Dermatol 2015; 173(2): 555-8.
[http://dx.doi.org/10.1111/bjd.13688] [PMID: 26104483]
[102]
Lonjou C, Borot N, Sekula P, et al. RegiSCAR study group. A european study of HLA-B in stevens-johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18(2): 99-107.
[http://dx.doi.org/10.1097/FPC.0b013e3282f3ef9c] [PMID: 18192896]
[103]
Zineh I, Mummaneni P, Lyndly J, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics 2011; 12(12): 1741-9.
[http://dx.doi.org/10.2217/pgs.11.131] [PMID: 22118056]
[104]
Sukasem C, Jantararoungtong T, Kuntawong P, et al. HLA-B * 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in thailand. Front Pharmacol 2016; 7(7): 186.
[http://dx.doi.org/10.3389/fphar.2016.00186] [PMID: 27486401]
[105]
Gonçalo M, Coutinho I, Teixeira V, et al. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and stevens-johnson syndrome/toxic epidermal necrolysis in a portuguese population. Br J Dermatol 2013; 169(3): 660-5.
[http://dx.doi.org/10.1111/bjd.12389] [PMID: 23600531]
[106]
Yu K-H, Yu C-Y, Fang Y-F. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. Int J Rheum Dis 2017; 20(9): 1057-71.
[http://dx.doi.org/10.1111/1756-185X.13143] [PMID: 28857441]
[107]
Wu R, Cheng YJ, Zhu LL, et al. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget 2016; 7(49): 81870-9.
[http://dx.doi.org/10.18632/oncotarget.13250] [PMID: 27835909]
[108]
Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007; 20(5): 391-5.
[http://dx.doi.org/10.1111/j.1525-139X.2007.00270.x] [PMID: 17897242]
[109]
Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing. Clin Pharmacol Ther 2013; 93(2): 153-8.
[http://dx.doi.org/10.1038/clpt.2012.209] [PMID: 23232549]
[110]
Lee T, Lee YS, Yoon S-Y, et al. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. J Am Acad Dermatol 2013; 69(3): 407-15.
[http://dx.doi.org/10.1016/j.jaad.2013.03.024] [PMID: 23632341]
[111]
Hung C-C, Liu W-C, Kuo M-C, Lee C-H, Hwang S-J, Chen H-C. Acute renal failure and its risk factors in stevens-johnson syndrome and toxic epidermal necrolysis. Am J Nephrol 2009; 29(6): 633-8.
[http://dx.doi.org/10.1159/000195632] [PMID: 19155617]
[112]
García Rodríguez LA, Ruigómez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the united kingdom. Pharmacotherapy 1997; 17(4): 721-8.
[PMID: 9250549]
[113]
de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58(1): 71-80.
[http://dx.doi.org/10.1111/j.1365-2125.2004.02133.x] [PMID: 15206996]
[114]
Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004; 36(2): 301-12.
[http://dx.doi.org/10.1081/DMR-120034148] [PMID: 15237856]
[115]
Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011; 8(4): 202-11.
[http://dx.doi.org/10.1038/nrgastro.2011.22] [PMID: 21386809]
[116]
Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4(6): 489-99.
[http://dx.doi.org/10.1038/nrd1750] [PMID: 15931258]
[117]
Waring JF, Anderson MG. Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr Opin Drug Discov Devel 2005; 8(1): 59-65.
[PMID: 15679173]
[118]
Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the united states: analysis of the united network for organ sharing database. Liver Transpl 2009; 15(7): 719-29.
[http://dx.doi.org/10.1002/lt.21692] [PMID: 19562705]
[119]
Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug induced liver injury network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the united states. Drug Saf 2009; 32(1): 55-68.
[http://dx.doi.org/10.1053/j.gastro.2008.09.011] [PMID: 18955056]
[120]
Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010; 138(7): 2246-59.
[http://dx.doi.org/10.1053/j.gastro.2010.04.001] [PMID: 20394749]
[121]
Ostapowicz G, Fontana RJ, Schiødt FV, et al. U.S. Acute liver failure study group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the united states. Ann Intern Med 2002; 137(12): 947-54.
[http://dx.doi.org/10.7326/0003-4819-137-12-200212170-00007] [PMID: 12484709]
[122]
Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol 2015; 89(3): 327-34.
[http://dx.doi.org/10.1007/s00204-015-1456-2] [PMID: 25618544]
[123]
Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82(6): 1826-32.
[http://dx.doi.org/10.1172/JCI113798] [PMID: 3198757]
[124]
Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22(2): 145-55.
[http://dx.doi.org/10.1055/s-2002-30105] [PMID: 12016546]
[125]
Worm M, Francuzik W, Renaudin J-M, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from the european anaphylaxis registry. Allergy 2018; 73(6): 1322-30.
[http://dx.doi.org/10.1111/all.13380] [PMID: 29318637]
[126]
Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16(23): 3041-53.
[http://dx.doi.org/10.2174/092986709788803097] [PMID: 19689281]
[127]
Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10(9): 1467-87.
[http://dx.doi.org/10.2217/pgs.09.111] [PMID: 19761370]
[128]
Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6(11): 904-16.
[http://dx.doi.org/10.1038/nrd2423] [PMID: 17971785]
[129]
Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol 1999; 12(5): 387-95.
[http://dx.doi.org/10.1021/tx980249i] [PMID: 10328748]
[130]
Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513-39.
[http://dx.doi.org/10.1146/annurev.pharmtox.47.120505.105150] [PMID: 16879083]
[131]
Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2(4): 301-5.
[http://dx.doi.org/10.1097/00130832-200208000-00003] [PMID: 12130944]
[132]
Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8(3): 186-95.
[http://dx.doi.org/10.1038/sj.tpj.6500458] [PMID: 17505501]
[133]
Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166(7): 916-9.
[http://dx.doi.org/10.1164/rccm.2108091] [PMID: 12359646]
[134]
Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology 1999; 117(5): 1181-6.
[http://dx.doi.org/10.1016/S0016-5085(99)70404-X] [PMID: 10535882]
[135]
Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53(6): 1049-53.
[http://dx.doi.org/10.1016/j.jhep.2010.05.033] [PMID: 20800921]
[136]
O’Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47(5): 717-20.
[http://dx.doi.org/10.1136/gut.47.5.717] [PMID: 11034591]
[137]
Andrade RJ, Lucena MI, Alonso A, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004; 39(6): 1603-12.
[http://dx.doi.org/10.1002/hep.20215] [PMID: 15185301]
[138]
Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41(7): 816-9.
[http://dx.doi.org/10.1038/ng.379] [PMID: 19483685]
[139]
Mallal S, Phillips E, Carosi G, et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358(6): 568-79.
[http://dx.doi.org/10.1056/NEJMoa0706135] [PMID: 18256392]
[140]
Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29(4): 337-47.
[http://dx.doi.org/10.1055/s-0029-1240002] [PMID: 19826967]
[141]
Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11(3): 477-505.
[http://dx.doi.org/10.1016/j.cld.2007.06.003] [PMID: 17723916]
[142]
Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49(6): 2001-9.
[http://dx.doi.org/10.1002/hep.22895] [PMID: 19475693]
[143]
Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42(2): 481-9.
[http://dx.doi.org/10.1002/hep.20800] [PMID: 16025496]
[144]
Praga M, Sevillano A, Auñón P, González E. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 2015. 30(9): 1472-9.
[http://dx.doi.org/10.1093/ndt/gfu326]
[145]
Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54(3): 179-90.
[PMID: 11020015]
[146]
Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 2004; 19(1): 8-11.
[http://dx.doi.org/10.1093/ndt/gfg464] [PMID: 14671029]
[147]
Praga M, González E. Acute interstitial nephritis. Kidney Int 2010; 77(11): 956-61.
[http://dx.doi.org/10.1038/ki.2010.89] [PMID: 20336051]
[148]
Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis 2014; 64(4): 558-66.
[http://dx.doi.org/10.1053/j.ajkd.2014.04.027] [PMID: 24927897]
[149]
Muriithi AK, Leung N, Valeri AM, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 2015; 87(2): 458-64.
[http://dx.doi.org/10.1038/ki.2014.294] [PMID: 25185078]
[150]
Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol 2010; 6(8): 461-70.
[http://dx.doi.org/10.1038/nrneph.2010.71] [PMID: 20517290]
[151]
Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 2004. 19(6): 1441-6.
[http://dx.doi.org/10.1093/ndt/gfh137]
[152]
Esteve JB, Launay-Vacher V, Brocheriou I, Grimaldi A, Izzedine H. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. Clin Nephrol 2005; 63(5): 385-9.
[http://dx.doi.org/10.5414/CNP63385] [PMID: 15909599]
[153]
Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13(5): 629-38.
[http://dx.doi.org/10.1002/ibd.20099] [PMID: 17243140]
[154]
Rossert J. Drug-induced acute interstitial nephritis. Kidney Int 2001; 60(2): 804-17.
[http://dx.doi.org/10.1046/j.1523-1755.2001.060002804.x] [PMID: 11473672]
[155]
Parkhie SM, Fine DM, Lucas GM, Atta MG. Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol 2010; 5(5): 798-804.
[http://dx.doi.org/10.2215/CJN.08211109] [PMID: 20338962]
[156]
Airy M, Raghavan R, Truong LD, Eknoyan G. Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrol Dial Transplant 2013; 28(10): 2502-9.
[http://dx.doi.org/10.1093/ndt/gft241] [PMID: 24009289]
[157]
Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012; 13: 39.
[http://dx.doi.org/10.1186/1465-9921-13-39] [PMID: 22651223]
[158]
Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med 2018; 7(10)e356
[http://dx.doi.org/10.3390/jcm7100356] [PMID: 30326612]
[159]
Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of greater paris. Eur Respir J 2017; 50(2)1602419
[http://dx.doi.org/10.1183/13993003.02419-2016] [PMID: 28775045]
[160]
Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150(4): 967-72.
[http://dx.doi.org/10.1164/ajrccm.150.4.7921471] [PMID: 7921471]
[161]
Roelandt M, Demedts M, Callebaut W, et al. Epidemiology of interstitial lung disease (ILD) in flanders: registration by pneumologists in 1992-1994. Working group on ILD, VRGT. Vereniging voor respiratoire gezondheidszorg en tuberculosebestrijding. Acta Clin Belg 1995; 50(5): 260-8.
[http://dx.doi.org/10.1080/17843286.1995.11718459] [PMID: 8533525]
[162]
Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central denmark. Respir Med 2014; 108(5): 793-9.
[http://dx.doi.org/10.1016/j.rmed.2013.09.002] [PMID: 24636811]
[163]
Romagnoli M, Bigliazzi C, Casoni G, et al. The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25(1): 36-45.
[PMID: 19070259]
[164]
Tamura M, Saraya T, Fujiwara M, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist 2013; 18(4): 454-9.
[http://dx.doi.org/10.1634/theoncologist.2012-0248] [PMID: 23404815]
[165]
Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015; 170(2): 179-84.
[http://dx.doi.org/10.1111/bjh.13419] [PMID: 25891777]
[166]
Sahin IH, Geyer AI, Kelly DW, O’Reilly EM. Gemcitabine-related pneumonitis in pancreas adenocarcinoma-an infrequent event: elucidation of risk factors and management implications. Clin Colorectal Cancer 2016; 15(1): 24-31.
[http://dx.doi.org/10.1016/j.clcc.2015.08.003] [PMID: 26395520]
[167]
Sato T, Inokuma S, Sagawa A, et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48(10): 1265-8.
[http://dx.doi.org/10.1093/rheumatology/kep227] [PMID: 19651883]
[168]
Ohnishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003; 58(10): 872-5.
[http://dx.doi.org/10.1136/thorax.58.10.872] [PMID: 14514942]
[169]
Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology 2002; 224(3): 852-60.
[http://dx.doi.org/10.1148/radiol.2243011236] [PMID: 12202725]
[170]
Delanoy N, Pécuchet N, Fabre E, et al. Bleomycin-induced pneumonitis in the treatment of ovarian sex cord-stromal tumors: a systematic review and meta-analysis. Int J Gynecol Cancer 2015; 25(9): 1593-8.
[http://dx.doi.org/10.1097/IGC.0000000000000530] [PMID: 26308607]
[171]
Bhatia S, Hanna N, Ansari R, et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38(1): 73-7.
[http://dx.doi.org/10.1016/S0169-5002(02)00145-9] [PMID: 12367796]
[172]
Mankikian J, Favelle O, Guillon A, et al. Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respir Med 2014; 108(4): 638-46.
[http://dx.doi.org/10.1016/j.rmed.2014.01.014] [PMID: 24565600]
[173]
Bongard V, Marc D, Philippe V, Jean-Louis M, Maryse L-M. Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone. Am J Ther 2006; 13(4): 315-9.
[http://dx.doi.org/10.1097/00045391-200607000-00007] [PMID: 16858166]
[174]
Nishimura M, Toyoda M, Takenaka K, et al. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2016; 77(6): 1165-70.
[http://dx.doi.org/10.1007/s00280-016-3026-6] [PMID: 27100735]
[175]
Wijnen PAHM, Drent M, Nelemans PJ, et al. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the netherlands. Drug Saf 2008; 31(12): 1125-34.
[http://dx.doi.org/10.2165/0002018-200831120-00008] [PMID: 19026029]
[176]
Koo LC, Clark JA, Quesenberry CP, et al. National differences in reporting ‘pneumonia’ and ‘pneumonia interstitial’: an analysis of the WHO international drug monitoring database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 2005; 14(11): 775-87.
[http://dx.doi.org/10.1002/pds.1071] [PMID: 15654720]
[177]
O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14(1): 91-6.
[http://dx.doi.org/10.1093/annonc/mdg020] [PMID: 12488299]
[178]
Hamada T, Yasunaga H, Nakai Y, et al. Interstitial lung disease associated with gemcitabine: a Japanese retrospective cohort study. Respirology 2016; 21(2): 338-43.
[http://dx.doi.org/10.1111/resp.12665] [PMID: 26775618]
[179]
Osawa M, Kudoh S, Sakai F, et al. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol 2015; 20(6): 1063-71.
[http://dx.doi.org/10.1007/s10147-015-0834-3] [PMID: 25967287]
[180]
Tomii K, Kato T, Takahashi M, et al. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Jpn J Clin Oncol 2017; 47(4): 350-6.
[http://dx.doi.org/10.1093/jjco/hyx010] [PMID: 28158568]
[181]
Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 japanese patients with non-small-cell lung cancer. Cancer Sci 2014; 105(12): 1584-90.
[http://dx.doi.org/10.1111/cas.12550] [PMID: 25287435]
[182]
Johkoh T, Sakai F, Kusumoto M, et al. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib-a cohort study. Clin Lung Cancer 2014; 15(6): 448-54.
[http://dx.doi.org/10.1016/j.cllc.2014.06.003] [PMID: 25043209]
[183]
Sakurada T, Kakiuchi S, Tajima S, et al. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 2015; 49(4): 398-404.
[http://dx.doi.org/10.1177/1060028014566446] [PMID: 25565405]
[184]
White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182(3): 396-403.
[http://dx.doi.org/10.1164/rccm.200911-1720OC] [PMID: 20194812]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy